Researchers have uncovered a way the malaria parasite becomes resistant to an investigational drug. The discovery also is relevant for other infectious diseases including bacterial infections and tuberculosis. Fosmidomycin, an antibiotic, is being evaluated against malaria in phase 3 clinical trials in combination with other antimalarial drugs.